Skip to main content
Premium Trial:

Request an Annual Quote

T2 Biosystems Regains Compliance With Nasdaq Listing Requirements

NEW YORK – T2 Biosystems announced Wednesday it has regained compliance with the Nasdaq's minimum bid price continued listing requirement. 

In April, the company was notified it wasn't in compliance with the requirement because its common stock failed to maintain a minimum bid price of $1.00 for 30 consecutive business days. 

The Lexington, Massachusetts-based firm regained compliance by maintaining a minimum closing bid price of at least $1.00 for 10 consecutive trading days, which it did on June 15.

At the close of the market Tuesday, T2 Bio shares were down nearly 6 percent at $1.54.

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.